CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories
| Autor: | Christian Deuschle, Thomas Gasser, Inga Lieplt-Scarfone, Benjamin Riebenbauer, Stefanie Lerche, Monique Dehnert, Isabel Wurster, Milan Zimmermann, Elke Stransky, Sarah Wiethoff, Kathrin Brockmann, Gerrit Machetanz, Lea Rietschel, Benjamin Röben |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Neurofilament light PINK1 Disease Gastroenterology etiology [Cognitive Dysfunction] 03 medical and health sciences Cognition 0302 clinical medicine Cerebrospinal fluid Neurofilament Proteins cerebrospinal fluid [Parkinson Disease] Internal medicine medicine Humans Cognitive Dysfunction ddc:610 Cognitive decline Aged business.industry Age Factors Montreal Cognitive Assessment Parkinson Disease cerebrospinal fluid [Neurofilament Proteins] 030104 developmental biology Neurology Cohort Disease Progression Neurology (clinical) complications [Parkinson Disease] business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Movement disorders 35(7), 1138-1144 (2020). doi:10.1002/mds.28056 |
| ISSN: | 1531-8257 0885-3185 |
| DOI: | 10.1002/mds.28056 |
| Popis: | BACKGROUND Neurofilament light protein is an unspecific biofluid marker that reflects the extent of neuronal/axonal damage and thereby offers the chance monitor disease severity and progression. The objective of this study was to investigate cerebrospinal fluid (CSF) levels of neurofilament light protein in Parkinson's disease (PD) patients with clinical trajectories of motor and cognitive function longitudinally. METHODS CSF neurofilament light protein levels were assessed in 371 PDsporadic , 126 genetic PD patients (91 PDGBA , 8 PDLRRK2 , 21 PDPRKN/PINK1/DJ1_heterozygous , 6 PDPRKN/PINK1/DJ1_homozygous ), and 71 healthy controls. Participants were followed up longitudinally for up to 8 years. RESULTS At baseline, mean CSF neurofilament light protein levels were highest in PD patients with cognitive impairment (Montreal Cognitive Assessment score ≤ 25; 1207 pg/mL) but also higher in PD patients with normal cognitive function (757 pg/mL) compared with healthy controls (593 pg/mL; P ≤ 0.001). In healthy controls and in PD patients older age was associated with higher CSF levels of neurofilament light protein (P ≤ 0.001). In PD patients, male gender, older age at onset, longer disease duration, higher Hoehn and Yahr stages, higher UPDRS-III scores, and lower Montreal Cognitive Assessment scores were associated with higher CSF levels of neurofilament light protein (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text